{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:58:17Z","timestamp":1790546297012,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22301089"],"award-info":[{"award-number":["22301089"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.heliyon.2024.e37543","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T17:41:06Z","timestamp":1725644466000},"page":"e37543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A disproportionality analysis of sunitinib in the FDA adverse event reporting system (FAERS)"],"prefix":"10.1016","volume":"10","author":[{"given":"Wenbin","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4260-1794","authenticated-orcid":false,"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangning","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.heliyon.2024.e37543_bib1","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nrd2380","article-title":"Molecular basis for sunitinib efficacy and future clinical development","volume":"6","author":"Faivre","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.heliyon.2024.e37543_bib3","article-title":"Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer","volume":"13","author":"Xu","year":"2023","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e37543_bib4","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.ctrv.2011.12.002","article-title":"Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials","volume":"38","author":"Mackey","year":"2012","journal-title":"Cancer Treat Rev."},{"issue":"Suppl 1","key":"10.1016\/j.heliyon.2024.e37543_bib5","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.21037\/gs.2019.10.18","article-title":"Novel treatments for anaplastic thyroid carcinoma","volume":"9","author":"Ferrari","year":"2020","journal-title":"Gland Surg."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e37543_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21010010","article-title":"Multikinase inhibitor treatment in thyroid cancer","volume":"21","author":"Ancker","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e37543_bib7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12029-018-0065-8","article-title":"Systemic treatment of patients with advanced, unresectable hepatocellular carcinoma: emergence of therapies","volume":"49","author":"Sun","year":"2018","journal-title":"J. Gastrointest. Cancer"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e37543_bib8","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jtho.2023.04.009","article-title":"Style (NCT03449173): a phase 2 trial of sunitinib in patients with type B3 thymoma or thymic carcinoma in second and further lines","volume":"18","author":"Proto","year":"2023","journal-title":"J. Thorac. Oncol. : official publication of the International Association for the Study of Lung Cancer"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e37543_bib9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00432-020-03129-6","article-title":"New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer","volume":"146","author":"Qiang","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"10431","key":"10.1016\/j.heliyon.2024.e37543_bib10","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0140-6736(23)02554-0","article-title":"Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial","volume":"403","author":"Baudin","year":"2024","journal-title":"Lancet (London, England)"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e37543_bib11","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nrd2380","article-title":"Molecular basis for sunitinib efficacy and future clinical development","volume":"6","author":"Faivre","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e37543_bib12","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/sj.bjc.6605552","article-title":"Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis","volume":"102","author":"Cella","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"9544","key":"10.1016\/j.heliyon.2024.e37543_bib13","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet (London, England)"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e37543_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e37543_bib15","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1158\/1535-7163.MCT-10-1124","article-title":"New insights into molecular mechanisms of sunitinib-associated side effects","volume":"10","author":"Aparicio-Gallego","year":"2011","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.heliyon.2024.e37543_bib16","article-title":"Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Endocrinol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e37543_bib17","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e37543_bib18","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e37543_bib19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2022.08.019","article-title":"Epidemiology of renal cell carcinoma: 2022 update","volume":"82","author":"Bukavina","year":"2022","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e37543_bib20","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e37543_bib21","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/14740338.2017.1323867","article-title":"Empirical estimation of under-reporting in the US Food and Drug Administration adverse event reporting system (FAERS)","volume":"16","author":"Alatawi","year":"2017","journal-title":"Expet Opin. Drug Saf."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e37543_bib22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1179\/2295333715Y.0000000065","article-title":"Pleural and pericardial effusions combined with ascites in a patient with severe sunitinib-induced hypothyroidism","volume":"71","author":"Kust","year":"2016","journal-title":"Acta Clin. Belg."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e37543_bib23","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ando.2023.03.009","article-title":"Endocrine-related adverse conditions induced by tyrosine kinase inhibitors","volume":"84","author":"De","year":"2023","journal-title":"Ann. Endocrinol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e37543_bib24","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3747\/co.2007.132","article-title":"Phase II testing of sunitinib: the National Cancer Institute of Canada clinical trials group IND program trials IND. 182\u2013185","volume":"14","author":"Buckstein","year":"2007","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.heliyon.2024.e37543_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-12-598","volume":"12","author":"Collinson","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.heliyon.2024.e37543_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13104-018-3137-8","article-title":"Treatment outcome of anti-angiogenesis through VEGF-pathway in the management of gastric cancer: a systematic review of phase II and III clinical trials","volume":"11","author":"Mawalla","year":"2018","journal-title":"BMC Res. Notes"},{"issue":"15_suppl","key":"10.1016\/j.heliyon.2024.e37543_bib27","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.16108","article-title":"A phase II study of the efficacy and safety of sunitinib in treatment-naive and pretreated Japanese patients (pts) with metastatic renal cell carcinoma (mRCC)","volume":"26","author":"Uemura","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e37543_bib28","series-title":"Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor (TKI) Treatment in Patients with Metastatic Renal Cell Carcinoma (mRCC): A Network Meta-Analysis Based on Phase II\/III Randomised Clinical Trials (RCTs)","author":"Manz","year":"2019"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e37543_bib29","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1183\/09031936.00048212","article-title":"Lung toxicity in a patient treated with sunitinib","volume":"40","author":"Boyle","year":"2012","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.heliyon.2024.e37543_bib30","first-page":"2","article-title":"Interstitial lung disease: case report","volume":"1437","author":"Sekiguchi","year":"2013","journal-title":"Reactions"},{"key":"10.1016\/j.heliyon.2024.e37543_bib31","first-page":"23","article-title":"Radiation recall pneumonitis in an elderly patient: case report","volume":"1444","author":"Yuasa","year":"2013","journal-title":"Reactions"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e37543_bib32","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000258880","article-title":"Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib","volume":"77","author":"Lipworth","year":"2009","journal-title":"Oncology"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e37543_bib33","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/archderm.144.8.1081","article-title":"Palmar-plantar erythrodysesthesia secondary to sunitinib treatment resulting in necrotic foot syndrome aggravated by background diabetic vascular disease","volume":"144","author":"Guenova","year":"2008","journal-title":"Arch. Dermatol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e37543_bib34","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4236\/pp.2016.78043","article-title":"Pazopanib induced hand-foot syndrome in a patient previously treated with sunitinib: a possible cumulative skin toxicity?","volume":"7","author":"Cozzani","year":"2016","journal-title":"Pharmacol. Pharm."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024135748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024135748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:31:43Z","timestamp":1790544703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024135748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":33,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2405844024135748"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e37543","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A disproportionality analysis of sunitinib in the FDA adverse event reporting system (FAERS)","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e37543","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e37543"}}